Mediwound reports q1 loss per share of $0.09

Mediwound reports first quarter 2020 financial results and provides corporate update.q1 loss per share $0.09.q1 revenue $4.4 million versus refinitiv ibes estimate of $4.1 million.q1 earnings per share estimate $-0.14 -- refinitiv ibes data.first delivery of nexobrid is currently expected in q3 of 2020.company expects cash use for ongoing operating activities in 2020 to be in range of $8 million to $10 million.at this time company does not expect any disruptions to its manufacturing operations and global supply chain.company expects cash use for ongoing operating activities in 2020 to be in range of $8 million to $10 million.as of march 31, 2020, company had $27.3 million in cash and short-term bank deposits and carries no debt.at this time, company cannot predict extent or duration of impact of covid-19 outbreak on its ongoing financial and operating results.pre-defined interim assessment is anticipated in first half of 2021 for u.s. escharex phase 2 adaptive design study.
MDWD Ratings Summary
MDWD Quant Ranking